×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Head & Neck Cancer

Heather Stringer
Patients with head and neck cancer may soon have more effective, less toxic choices as immunotherapy moves into first-line treatment and novel targeted drugs are explored.
 
Katie Kosko
Compared with the general population, men and women with type 2 diabetes face greater risk of developing certain cancers, such as colorectal, kidney, liver and more.
 
Maria Campos
This essay was written by Maria Campos nominating Mary Kernan, RN, OCN, of Smilow Cancer Center At Yale New Haven Health, New Haven, Connecticut, for CURE®'s Extraordinary Healer® Award.
Jessica Skarzynski
Here are the top 5 CURE stories for April 2019.
Kristie L. Kahl
Use of two medicated mouthwashes reduced pain from oral mucositis during the first four hours after administration; however, the results were not deemed clinically different when compared with placebo.
Jessica Skarzynski
In this Special Edition of CURE Talks Cancer, we chat with Poison drummer and throat cancer survivor Rikki Rockett about his cancer journey and why it's important to "Open Up and Say... Ahh!" during Oral, Head and Neck Cancer Awareness Week. 
Alexandra Guadagno
From artificial intelligence to a surprise FDA resignation, check out this week’s quick overview of what is making headlines in the cancer space.
Gregory Carroll
A five-year lesson in cancer, worry and hope.
Kristie L. Kahl
The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Jessica Skarzynski
A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other